Found 28 articles for: "Melasma"
Fundamentals of Hyperpigmentation Disorders: Causes, Concerns, and Treatment Strategies, Particularly in Skin of Color Patients
October 2026 | Volume 25 | Issue 10 | Original Article | 926 | Copyright © October 2026
Background: Pigmentary disorders, including hyperpigmentation, are among the most common dermatologic diagnoses in individuals with skin of color (SOC), particularly individuals ...
Read MoreEfficacy and Tolerability of a Topical Pigment-Correcting Serum in Melasma and Postinflammatory Hyperpigmentation
July 2026 | Volume 25 | Issue 7 | Original Article | 596 | Copyright © July 2026
Background: Melasma and postinflammatory hyperpigmentation (PIH) are common disorders of hyperpigmentation of key aesthetic concern. This study assessed the efficacy and tolerabi...
Read MoreHydroquinone and Emerging Depigmenting Agents: Clinical Guidelines, Regulatory History, and Global Safety Considerations
April 2026 | Volume 25 | Issue 4 | Original Article | 363 | Copyright © April 2026
Hydroquinone has long served as the gold standard for hyperpigmentation treatment, but safety concerns, regulatory changes, and growing interest in non-hydroquinone therapies have prompted reeval...
Read MoreA Novel Topical Agent for the Management of Hyperpigmentation, Including Melasma and Age Spots
January 2026 | Volume 25 | Issue 1 | Original Article | 75 | Copyright © January 2026
Background/Objectives: Melasma and age spots are among the most persistent and difficult-to-treat forms of hyperpigmentation. While traditional therapies offer some clinical effi...
Read MoreEvaluation of an Advanced, Multimodal Skin Tone Correcting Serum in Participants With Mild-to-Severe Dyschromia and Hyperpigmentation
January 2026 | Volume 25 | Issue 1 | Original Article | 36 | Copyright © January 2026
Background: A new multimodal skin tone correcting serum formulated with b.r.y.t.e.r. (brown, red, and yellow tones with enhanced resurfacing) technology (EV-I) targets brown, red...
Read MoreA Randomized, Controlled, Split-Face, Double-Blind Study Comparing Topical Malassezin to Hydroquinone 4% for Melasma
January 2026 | Volume 25 | Issue 1 | Original Article | 25 | Copyright © January 2026
Background: Previous studies have documented the capacity of malassezin to brighten the skin. It represents a novel agent for the treatment of hyperpigmentation.Clinical Evaluation of Thiamidol-Containing Formulations for the Visual Management of Facial Hyperpigmentation
December 2025 | Volume 24 | Issue 12 | Original Article | 1195 | Copyright © December 2025
Read MorePhotoprotection Efficacy of Sun Protection Factor and Iron Oxide Formulations in Diverse Skin With Melasma and Photodamage
July 2025 | Volume 24 | Issue 7 | Original Article | 662 | Copyright © July 2025
Visible light (400-700nm) comprises 45% of the sunlight spectrum and can induce both immediate and persistent skin darkening, as well as worsen dyschromia, especially in the skin of color populat...
Read MoreThiamidol: A Breakthrough Innovation in the Treatment of Hyperpigmentation
June 2025 | Volume 24 | Issue 6 | Original Article | 608 | Copyright © June 2025
Cutaneous hyperpigmentation, including melasma, solar lentigines, and post-inflammatory hyperpigmentation (PIH), results in a significant impact on patients’ quality of life. Unfortunately,...
Read MoreError: 500: HTTP/2 500Gender, Racial, and Fitzpatrick Skin Type Representation in Melasma Clinical Trials
January 2025 | Volume 24 | Issue 1 | | 19 | Copyright © January 2025
Melasma, a symmetric pigmentary disorder, is more prevalent in women and individuals with darker skin tones. Despite its global prevalence, there is a notable gap in the understanding of gender, ...
Read MoreThe Burden of Melasma: Race, Ethnicity, and Comorbidities
August 2024 | Volume 23 | Issue 8 | Features | 691 | Copyright © August 2024
Introduction: In an effort to define the characteristics of populations affected by melasma, we utilized a large global health research network database from 108 health care orga...
Read MoreRepresentation of Skin of Color in Social Media Discussions on Melasma, Keloids, and Vitiligo
July 2024 | Volume 23 | Issue 7 | Original Article | 510 | Copyright © July 2024
Background: The prevalence of social media as a source of medical information has grown substantially in recent years, especially for skin conditions disproportionately affecting...
Read MoreEfficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma
July 2024 | Volume 23 | Issue 7 | Original Article | 529 | Copyright © July 2024
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.Objectiv...
Read MoreExpanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males
April 2024 | Volume 23 | Issue 4 | Editorials | e110 | Copyright © April 2024
Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action
February 2024 | Volume 23 | Issue 2 | Original Article | 9 | Copyright © February 2024
Background: Modified Kligman's formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent...
Read MoreTopical Treatments for Melasma and Post-inflammatory Hyperpigmentation
November 2023 | Volume 22 | Issue 11 | Original Article | 1118 | Copyright © November 2023
Background: Dyschromia is one of the most common reasons for patients to seek dermatological care, especially among individuals with skin of color. Most cases present as melasma ...
Read MoreError: 500: HTTP/2 500Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
April 2023 | Volume 22 | Issue 4 | | 386 | Copyright © April 2023
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. Howe...
Read MoreA Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas
December 2022 | Volume 21 | Issue 12 | Original Article | 1304 | Copyright © December 2022
Background: Hydroquinone is effective in melasma treatment, but side effects may limit its use. Silymarin cream may be a safer alternative. Objective: To compare the ...
Read MoreOral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen
April 2022 | Volume 21 | Issue 4 | Original Article | 393 | Copyright © April 2022
Melasma is a common disorder affecting millions of people around the world.1 It is a condition that can disrupt one’s self-esteem and overall quality of life.2 Melasma is c...
Read MoreA Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma
March 2022 | Volume 21 | Issue 3 | Editorials | 321 | Copyright © March 2022
Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
